MET and cancer: Similarly, pan-HER inhibitors and TNKS1/2 inhibitors are being evaluated in clinical trials as monotherapy or in combination with other drugs, such as MET inhibitors, in patients with advanced cancers or disease progression after >2 previous treatment regimens43–46.